Alignment Healthcare (NASDAQ: ALHC) operates Medicare Advantage plans powered by a technology-driven care model targeting high-need senior populations. An EVP's $550,000 open-market share sale has drawn attention, but the underlying Q1 numbers and the stock's sharp 52-week run tell a more substantive story.
At a Glance
- ALHC trading at $21.66, up 3.1% on the day, within a 52-week range of $13.05–$22.74
- Market cap: $4.52 billion; RSI: 66.94
- Q1 revenue of $1.24 billion, up 33.3% year over year
- Membership reached ~284,800, a 30.9% annual increase
- EVP Joseph Konowiecki sold 25,000 shares at $22.00 on June 18, 2026, under a Rule 10b5-1 plan
| Price | 21.66 USD |
|---|---|
| Day change | +0.66 (+3.1%) |
| 52-week range | 13.05 – 22.74 |
| Market cap | $4.52B |
| RSI (14) | 66.94 |
| Volume | 2,641,243 |
The Insider Sale in Context
According to a SEC Form 4 filing, Joseph S. Konowiecki, EVP of Corporate Affairs, sold 25,000 shares on June 18, 2026, at $22.00 per share — a transaction worth approximately $550,000. After the sale, he held 1,153,816 shares directly, a position valued at roughly $25.22 million at that session's close of $21.86. The transaction amounted to just over 2% of his pre-sale direct holdings.
Critically, the sale was executed under a prearranged Rule 10b5-1 trading plan adopted in March 2026. These plans are set up in advance, insulating the timing from any material non-public information the executive might later possess. That structural detail substantially limits how much weight investors should place on the transaction as a directional signal.
Q1 Operational Performance
Strip away the insider filing and what's left is a growth story that has been accelerating. In Q1 2026, Alignment posted revenue of $1.24 billion, up 33.3% from the prior-year period. Membership expanded 30.9% to approximately 284,800 — a scale threshold that matters in Medicare Advantage, where network breadth and cost management are intertwined.
The company also swung to net income of $11.4 million from a net loss in Q1 2025, while adjusted EBITDA climbed nearly 88% to $37.9 million. Management responded by raising the midpoint of full-year guidance across membership, revenue, adjusted gross profit, and adjusted EBITDA. CEO John Kao described the quarter as evidence that Alignment can "grow with discipline," pointing to measurable gains in sales execution, clinical operations, and cost control.
On a trailing-twelve-month basis, revenue stands at $4.26 billion with net income of $19.81 million — thin margins relative to top line, though the directional improvement is notable for a company that was loss-making not long ago.
What the Numbers Say
Valuation: At $21.66 with a $4.52 billion market cap, ALHC trades at a significant premium to earnings. TTM net income of $19.81 million against that market cap implies a P/E ratio well above 200x — a valuation that is pricing in substantial future growth rather than current profitability. The stock has gained roughly 56.6% over the past year, compressing the margin of safety for value-oriented buyers.
Momentum: The RSI of 66.94 places ALHC in elevated territory without crossing into the conventional overbought threshold of 70. That reading, combined with the price sitting just 4.7% below its 52-week high of $22.74, suggests the near-term trend remains constructive but the stock has limited technical headroom before momentum indicators begin to flash caution.
Yield: Alignment Healthcare does not pay a dividend, consistent with its growth-stage capital allocation priorities. Investors are entirely dependent on price appreciation for total return.
Bull Case
The bull argument centers on durable membership growth in a structurally expanding market — the Medicare Advantage enrollment pool continues to widen as the U.S. senior population grows. Alignment's technology-integrated model and direct plan ownership allow tighter margin management than many peers. The EBITDA trajectory, if sustained, could eventually justify the current multiple through earnings growth rather than multiple expansion.
Bear-Case Risks
The bear case is straightforward: the stock is priced for near-perfection at over 200x trailing earnings, leaving little buffer for execution missteps. Medicare Advantage reimbursement rates remain a persistent regulatory variable — CMS rate adjustments can materially alter unit economics across the industry. Margins, while improving, remain thin on a net income basis. A broader healthcare sector sell-off or a guidance miss in subsequent quarters could reprice the stock sharply given how much optimism is already embedded at these levels.
Frequently Asked Questions
Why did Alignment Healthcare's EVP sell shares?
Joseph Konowiecki sold 25,000 shares under a Rule 10b5-1 trading plan that was established in March 2026, meaning the sale was scheduled in advance and not necessarily tied to any view on the company's near-term prospects. He retained more than 1.15 million shares after the transaction.
What does Alignment Healthcare do?
Alignment Healthcare operates technology-enabled Medicare Advantage plans focused on high-need senior populations. Its model integrates direct plan ownership with a proprietary care platform designed to improve clinical outcomes while managing costs.
Is ALHC stock near its 52-week high?
As of June 21, 2026, ALHC was trading at $21.66 — approximately 4.7% below its 52-week high of $22.74, and well above its 52-week low of $13.05.
Does Alignment Healthcare pay a dividend?
No. Alignment Healthcare does not currently pay a dividend, directing capital toward growth initiatives rather than shareholder distributions.
Where ALHC Goes From Here
The Konowiecki filing is largely a distraction from the core question facing ALHC investors: whether management can continue converting rapid membership growth into durable earnings expansion. Q1 data points in the right direction, and the guidance raise signals internal confidence. At $21.66 and an RSI approaching overbought territory, the stock's next catalyst will need to come from the income statement, not the momentum chart.
